Bavarian Nordic: Should You Invest In This Biotech Company?

Bavarian Nordic is a Denmark-based biotechnology company that manufactures pharmaceutical preparations. The company focuses on the research, development, and manufacturing of life-saving vaccines, cancer immunotherapy, and travel health products. With a presence in selected markets worldwide, Bavarian Nordic has seen its stock price fluctuate and has been in the news for its role in addressing infectious diseases such as monkeypox and smallpox. So, is Bavarian Nordic a good investment opportunity or a potential buy for investors? Let's delve into the details and explore the prospects of this company in the healthcare sector.

Share buy-back program

On May 8, 2024, Bavarian Nordic A/S (OMX: BAVA) announced the initiation of a new share buy-back program, with the intention of buying back up to 162,288 of its own shares. The program was designed to meet the company's obligations arising from the share-based incentive programs for the Board of Directors and Executive Management, in line with the company's remuneration policy.

The share buy-back program was authorised at the annual general meeting on April 16, 2024, where it was decided that the company could purchase up to 10% of its share capital. The program was executed in compliance with Regulation (EU) No. 596/2014 of the European Parliament and the Council of 16 April 2014, which addresses market abuse and is supplemented by Regulation (EU) 2016/1052 of 8 March 2016. Together, these regulations constitute the Safe Harbour Regulation.

The company appointed Danske Bank A/S as the Lead Manager of the program, who acted independently when making decisions on trading with Bavarian Nordic A/S's shares. The maximum consideration for Bavarian Nordic A/S-shares purchased within the duration of the program was DKK 40 million, though based on the closing price of the company's share on May 7, 2024, the total consideration was expected to be approximately DKK 26 million. The program concluded on May 21, 2024, with the intended number of shares repurchased.

Bavarian Nordic A/S is a fully integrated vaccines company that focuses on the development, manufacturing, and commercialisation of life-saving vaccines. The company is a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Government, providing a non-replicating smallpox vaccine that has been approved by the FDA for protection against monkeypox.

Vaccines for infectious diseases

Bavarian Nordic is a global vaccine company that develops and manufactures vaccines for infectious diseases. The company was founded in 1994 and is headquartered in Denmark. With three decades of experience in vaccine development and manufacturing, Bavarian Nordic strives to improve and protect lives through innovative vaccines. The company's focus on infectious diseases aims to lower the risk and minimise the threat of deadly viruses for the greater good of the global community.

Bavarian Nordic's recent work in infectious disease vaccines includes the development and production of a new Ebola vaccine within a 12-month timeframe. In collaboration with Janssen, they have provided two million doses of the Ebola vaccine to the Democratic Republic of Congo and Rwanda for an ongoing vaccination campaign. Additionally, the company produces a smallpox vaccine for secure national stockpiles in the US, Canada, and Europe. During counter-bioterrorism efforts, Bavarian Nordic supplied 28 million doses of the smallpox vaccine to the US for emergency use.

The company also addresses other infectious diseases such as rabies, tick-borne encephalitis (TBE), and mpox. Rabies, transmitted through the saliva of infected mammals, claims approximately 59,000 lives globally each year, with children comprising 40% of those infected. TBE, on the other hand, is transmitted to humans by the bite of an infected tick or the consumption of unpasteurised dairy products from infected animals. Mpox, a rare viral infection related to smallpox, is mostly reported in Central and West Africa and can be transmitted from animals to humans, with possible human-to-human transmission as well.

Bavarian Nordic is committed to strengthening biosecurity and global preparedness against infectious diseases. The company's efforts in developing and providing access to effective vaccines contribute to reducing the risk and impact of these diseases on a global scale.

Cholera, rabies, encephalitis and typhoid vaccines

Cholera, rabies, encephalitis, and typhoid vaccines are all vaccines that protect against serious illnesses. Cholera is an illness spread through contaminated food or water, and it causes severe diarrhoea and vomiting. The cholera vaccine is an oral, live, attenuated (weakened) vaccine that is recommended for people aged 2 to 64 who are travelling to areas where cholera is present. It is important to note that the cholera vaccine is not 100% effective, and travellers should still take precautions with food and water.

Rabies is a serious and often fatal illness that infects the central nervous system. It is spread through contact with the saliva or neural tissue of an infected animal, typically through bites or scratches. The rabies vaccine is recommended for those at higher risk of exposure, such as those who work with potentially infected animals. The number of doses depends on the individual's level of risk and their previous vaccination history.

Encephalitis is an infection that occurs mainly in rural parts of Asia and is spread through the bite of an infected mosquito. Japanese encephalitis (JE) is a serious form of encephalitis that can cause fever, neck stiffness, seizures, and coma. The JE vaccine is recommended for travellers to areas where the disease is common and for those living in these areas.

Typhoid fever is a life-threatening disease spread through contaminated food or drink. It is caused by the bacteria Salmonella typhi and is common in many regions, including parts of Asia, Africa, the Caribbean, and Central and South America. There are two types of typhoid vaccines: inactivated (killed) and live, attenuated (weakened). The inactivated vaccine is given as an injection, while the live vaccine is administered orally. The choice between the two depends on individual factors, and the recommendation is to consult a healthcare provider.

Cancer immunotherapy

Bavarian Nordic A/S is a Denmark-based biotechnology company that focuses on developing innovative therapies and vaccines for infectious diseases and cancer. The company's cancer immunotherapy platform aims to provide the body with multiple weapons to produce safe, potent, and sustained anticancer activity in common and rare solid tumours.

Bavarian Nordic's cancer immunotherapy platform has shown promising preclinical advances, as published in Nature Communications in 2019. This approach involves administering a recombinant vaccine based on the company's viral MVA platform technology, which activates both the innate and adaptive arms of the immune system. The treatment has been successful in controlling established tumours by expanding tumour-specific killer CD8+ T cells and activating and expanding natural killer (NK) cells, which are crucial for antibody-mediated tumour killing.

The company's primary cancer immunotherapy product is CV301, which is being evaluated in combination with Roches's checkpoint inhibitor, atezolizumab (TECENTRIQ®), for the treatment of locally advanced or metastatic urothelial bladder cancer. However, the first phase of the study did not meet the efficacy threshold to progress to the second phase. Despite this setback, Bavarian Nordic remains committed to cancer immunotherapy and is directing its focus and resources towards BN-Brachyury and a new immuno-oncology strategy.

The BN-Brachyury vaccine candidate is currently in a Phase 2 trial for patients with advanced chordoma, a rare type of cancer that begins in the spine and base of the skull. This trial has shown promising results, with clinical activity observed in the first stage, leading to the expansion of enrollment. The company plans to initiate another trial of BN-Brachyury administered intravenously shortly.

In addition to its cancer immunotherapy efforts, Bavarian Nordic has a diverse portfolio of vaccines for infectious diseases, including Ebola, HPV, HBV, and HIV, developed through partnerships with organisations such as Janssen. The company also collaborates with the U.S. government on the development and supply of medical countermeasures, including the only FDA-approved, non-replicating smallpox vaccine.

Annual General Meeting

Bavarian Nordic A/S is a Denmark-based company that focuses on the research, development, and manufacturing of innovative life-saving vaccines. The company is committed to providing transparent information about its business, development programs, and results to its shareholders and the media.

The Annual General Meeting (AGM) is a crucial event in the company's calendar, offering a platform for shareholders to gather and receive updates on the company's performance and future plans. The AGM also facilitates the discussion and approval of various proposals and reports, including financial statements and the election of board members.

The 2023 AGM of Bavarian Nordic was held on March 30, 2023. The meeting addressed several key items on its agenda. The company's annual report for 2023 was adopted, along with the Board of Directors' proposal to transfer the company's results to 2024. The Remuneration Report for 2023 was also approved during the meeting.

The 2024 AGM of Bavarian Nordic A/S was held on April 16, 2024. This meeting saw the adoption of the 2023 Annual Report and the approval of the Remuneration Report for 2023. The Board of Directors and the Board of Management were discharged from liability. The meeting also witnessed the re-election of several board members, including Luc Debryune, Anders Gersel Pedersen, and Frank Verwiel. Additionally, Montse Montaner was newly elected to the Board of Directors, and Luc Debruyne was appointed as the Chairman, with Anders Gersel Pedersen serving as Deputy Chairman.

The AGM is a vital platform for the company to engage with its shareholders and seek their input and approval on critical matters. It provides an opportunity for the company to showcase its commitment to transparency and keep its shareholders informed about its activities and future direction.

Frequently asked questions